 Methods Design: The study recruited 120 men and women aged 18-70 years presenting with acute ischemic stroke 7-29 days and a NIHSS score of 7 and BI 50. Following baseline assessment MRI Brain, Whole Body PET scan, EEG brain, CT scan Brain and clinical examination including National Institute of Health Stroke Scale NIHSS, Barthel Index BI, modified Rankin Scale mRS, Glasgow Come Scale GCS, participants were randomly allocated to two groups: conventional management alone control group; or conventional management and autologous intravenous BMSCs transplantation experimental group. Bone marrow was aspirated under local anaesthesia and the isolated BMSCs cells injected intravenously within 4 hours. The patients were monitored with hemogram renalliver function tests, CT scan brain at 36 hrs and clinical examination for a week. The patients were followed up to one year with periodic MRI brain at 3 months, 6 months, EEG PET scan at 6 months and 1 year. The primary efficacy outcomes were difference between the two groups in the Modified Barthel index score and modified Rankin Scale score at six-month post-randomisation. The secondary efficacy outcomes are: NIHSS score at six-months and 1 year post-randomisation; and the modified Rankin scale score at 3 months and one year post-randomization, and functional status measured by barthel index in binary scale 60 or 60 at six months and one year post-randomization. Dose response analysis were done by comparing outcomes in patients receiving various doses of bone marrow mononuclear cells. 